UBS Group
GPCR icon

UBS Group’s Structure Therapeutics GPCR Stock Holding History

UBS Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-400
Closed -$27.8K – 10762
2025
Q4 		$27.8K Sell
400
-20,700
-98% -$845K ﹤0.01% 7576
2025
Q3 		$591K Sell
21,100
-10,100
-32% -$201K ﹤0.01% 5967
2025
Q2 		$647K Buy
31,200
+22,300
+251% +$490K ﹤0.01% 5802
2025
Q1 		$154K Sell
8,900
-27,400
-75% -$671K ﹤0.01% 6722
2024
Q4 		$984K Buy
+36,300
New +$1.29M ﹤0.01% 5309

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

UBS Group's GPCR Position: Q1 2026 in Review

UBS Group increased its Structure Therapeutics (GPCR) stake by 5.2% in Q1 2026, buying an estimated $715K and bringing the position to 212,919 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3320.

UBS Group first reported a position in GPCR in Q2 2023 and has held it in 11 quarters since. The position peaked at $14.1M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • UBS Group held 212,919 shares of Structure Therapeutics worth $10.3M as of Q1 2026.
  • UBS Group bought 10,442 Structure Therapeutics shares in Q1 2026, an estimated $715K.
  • Structure Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3320 holding.
  • UBS Group first reported a position in Structure Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • UBS Group's Structure Therapeutics position peaked at $14.1M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.